| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Androgen deprivation therapy in prostate cancer: new findings and questions for the future
|
Sartor, Oliver
|
|
2019
|
20 |
2 |
p. 176-177
|
artikel
|
| 2 |
Betel nut chewing in high-income countries—lack of awareness and regulation
|
Lechner, Matt
|
|
2019
|
20 |
2 |
p. 181-183
|
artikel
|
| 3 |
Big influences on anti-obesity strategies
|
|
|
2019
|
20 |
2 |
p. 165
|
artikel
|
| 4 |
Cabozantinib-related pneumothorax in rapidly responding patients with renal cell carcinoma
|
Iacovelli, Roberto
|
|
2019
|
20 |
2 |
p. e124
|
artikel
|
| 5 |
Challenges in anticancer drug R&D in China
|
Zhao, Shen
|
|
2019
|
20 |
2 |
p. 183-186
|
artikel
|
| 6 |
CheckMate 214 patient-reported outcomes: listening to our patients
|
Massari, Francesco
|
|
2019
|
20 |
2 |
p. 179-180
|
artikel
|
| 7 |
Checkpoint inhibitors in mesothelioma: hope for the future?
|
Bibby, Anna
|
|
2019
|
20 |
2 |
p. 172-174
|
artikel
|
| 8 |
CNS border posts against rituximab?
|
Kasenda, Benjamin
|
|
2019
|
20 |
2 |
p. 169-170
|
artikel
|
| 9 |
Correction to Lancet Oncol 2019; 20: 179–80
|
|
|
2019
|
20 |
2 |
p. e72
|
artikel
|
| 10 |
Correction to Lancet Oncol 2016; 17: 1590–98
|
|
|
2019
|
20 |
2 |
p. e71
|
artikel
|
| 11 |
Correction to Lancet Oncol 2017; 18: 904–16
|
|
|
2019
|
20 |
2 |
p. e71-e72
|
artikel
|
| 12 |
Correction to Lancet Oncol 2019; 20: 159–64
|
|
|
2019
|
20 |
2 |
p. e72
|
artikel
|
| 13 |
Correction to Lancet Oncol 2016; 17: 883–95
|
|
|
2019
|
20 |
2 |
p. e70
|
artikel
|
| 14 |
Degarelix improves suppression of ovarian function
|
Gourd, Elizabeth
|
|
2019
|
20 |
2 |
p. e73
|
artikel
|
| 15 |
Diagnosis of thyroid cancer using deep convolutional neural network models applied to sonographic images: a retrospective, multicohort, diagnostic study
|
Li, Xiangchun
|
|
2019
|
20 |
2 |
p. 193-201
|
artikel
|
| 16 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how?
|
Lam, Ka On
|
|
2019
|
20 |
2 |
p. e66
|
artikel
|
| 17 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? – Authors' reply
|
Henricks, Linda M
|
|
2019
|
20 |
2 |
p. e67
|
artikel
|
| 18 |
Essential TNM: a registry tool to reduce gaps in cancer staging information
|
Piñeros, Marion
|
|
2019
|
20 |
2 |
p. e103-e111
|
artikel
|
| 19 |
Farewell to four greats
|
The Lancet Oncology,
|
|
2019
|
20 |
2 |
p. 165
|
artikel
|
| 20 |
Insulin potentiation therapy for cancer?
|
Sissung, Tristan M
|
|
2019
|
20 |
2 |
p. 191-192
|
artikel
|
| 21 |
Limitations of simulation models for cervical cancer screening
|
Hammer, Anne
|
|
2019
|
20 |
2 |
p. e68
|
artikel
|
| 22 |
Limitations of simulation models for cervical cancer screening – Authors' reply
|
Malagón, Talía
|
|
2019
|
20 |
2 |
p. e69
|
artikel
|
| 23 |
Minimally invasive oesophagectomy for oesophageal cancer
|
Stirrups, Robert
|
|
2019
|
20 |
2 |
p. e74
|
artikel
|
| 24 |
Modulating the microbiome to improve therapeutic response in cancer
|
McQuade, Jennifer L
|
|
2019
|
20 |
2 |
p. e77-e91
|
artikel
|
| 25 |
More evidence for implant-based breast reconstruction
|
Rocco, Nicola
|
|
2019
|
20 |
2 |
p. 174-175
|
artikel
|
| 26 |
NHS England statistics and long-term plan
|
Burki, Talha Khan
|
|
2019
|
20 |
2 |
p. 187
|
artikel
|
| 27 |
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
|
Scherpereel, Arnaud
|
|
2019
|
20 |
2 |
p. 239-253
|
artikel
|
| 28 |
On algorithms, machines, and medicine
|
Coiera, Enrico
|
|
2019
|
20 |
2 |
p. 166-167
|
artikel
|
| 29 |
Optimisation of adaptive therapy for advanced Hodgkin lymphoma
|
Fitzgerald, Thomas J
|
|
2019
|
20 |
2 |
p. 167-168
|
artikel
|
| 30 |
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
|
Cella, David
|
|
2019
|
20 |
2 |
p. 297-310
|
artikel
|
| 31 |
Patients diagnosed with cancer at increased risk of suicide
|
Das, Manjulika
|
|
2019
|
20 |
2 |
p. e75
|
artikel
|
| 32 |
Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial
|
Polman, Nicole J
|
|
2019
|
20 |
2 |
p. 229-238
|
artikel
|
| 33 |
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
|
Casasnovas, René-Olivier
|
|
2019
|
20 |
2 |
p. 202-215
|
artikel
|
| 34 |
Pharmacologic management of cognitive impairment induced by cancer therapy
|
Karschnia, Philipp
|
|
2019
|
20 |
2 |
p. e92-e102
|
artikel
|
| 35 |
Promising new second-line therapy for Hodgkin lymphoma
|
Gourd, Elizabeth
|
|
2019
|
20 |
2 |
p. e76
|
artikel
|
| 36 |
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Zhu, Andrew X
|
|
2019
|
20 |
2 |
p. 282-296
|
artikel
|
| 37 |
Ramucirumab and the controversial role of α-fetoprotein in hepatocellular carcinoma
|
Abou-Alfa, Ghassan K
|
|
2019
|
20 |
2 |
p. 177-179
|
artikel
|
| 38 |
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
|
Bromberg, Jacoline E C
|
|
2019
|
20 |
2 |
p. 216-228
|
artikel
|
| 39 |
Self-collected versus clinician-collected samples for HPV testing
|
Lynge, Elsebeth
|
|
2019
|
20 |
2 |
p. 170-171
|
artikel
|
| 40 |
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial
|
Denham, James W
|
|
2019
|
20 |
2 |
p. 267-281
|
artikel
|
| 41 |
Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort study
|
Potter, Shelley
|
|
2019
|
20 |
2 |
p. 254-266
|
artikel
|
| 42 |
Skepticism about new US Government hospital pricing transparency rule
|
Furlow, Bryant
|
|
2019
|
20 |
2 |
p. 188
|
artikel
|
| 43 |
Surgery or a watch-and-wait approach for rectal cancer?
|
Rullier, Eric
|
|
2019
|
20 |
2 |
p. 189-190
|
artikel
|
| 44 |
Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective
|
Lievens, Yolande
|
|
2019
|
20 |
2 |
p. e112-e123
|
artikel
|
Tijdschrift beschrijving